Nanjing King's Generic Palonosetron Hydrochloride Receives Approval in the U.S.
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (œHelsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in...
Glenmark Pharmaceuticals on Monday said it has launched a medication for prevention of chemotherapy-induced nausea and vomiting, under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company. The company has introduced IV injection formulation Akynzeo IV in a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute IV injection, the Mumbai-based drug maker said in a statement.
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a...
FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.
FDA Confirms Paragraph IV Patent Litigation for Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride
Baxter Healthcare `s Generic Palonosetron Hydrochloride Receives Approval In US
Emcure Pharms` Generic Palonosetron Hydrochloride Receives Approval In US
Accord Hlthcare`s Generic Palonosetron Hydrochloride Receives Approval In US
Lugano, Switzerland, and Milan, Italy, September 18, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, and Italfarmaco, an Italy-based multinational pharmaceutical group committed to safeguard people’s health, today announce an abstract has been accepted for oral presentation at the ESMO Virtual Congress 2020 taking place from September 19-21. Full details of the presentation are below.